All

Phase 3 Data Published for Once-Nightly OSA Drug Candidate AD109

Results from the SynAIRgy trial show the investigational oral therapy AD109 significantly reduced airway obstruction and improved oxygenation in patients with obstructive sleep apnea.

Incannex Healthcare Commences DReAMzz Clinical Study for IHL-42X in OSA
Alkermes Reports Positive Phase 3 Results for LUMRYZ in Idiopathic Hypersomnia
Alkermes to Present Sustained Efficacy Data for Alixorexton in Narcolepsy Type 1
Incannex Updates Clinical Pathway for Sleep Apnea Drug Candidate IHL-42X
Phase 2 Explore-OSA Trial: Lorundrostat Reduces Blood Pressure But Not AHI in Sleep Apnea Patients
Nexalin Announces Pivotal Trial of HALO Clarity to Support FDA Submission for Insomnia

All

First Patient Dosed in Phase 3 Trial of Solriamfetol for Major Depressive Disorder with Excessive Daytime Sleepiness

The CLARITY trial utilizes a randomized withdrawal design to assess time to relapse of depressive symptoms in patients with major depressive disorder and excessive daytime sleepiness.

All

New Data Suggests Best Orexin Receptor Agonists Are Still to Come

As the first orexin-2 receptor agonist for narcolepsy nears FDA approval, a preclinical compound shows promise for its higher potency.

First Orexin Agonist in Phase 3 Trials for Narcolepsy

May 16, 2025 | Emerging Compounds, Narcolepsy

A phase 3 readout is anticipated later this year.

New Trial Reveals Sustained Benefits for Investigational Sleep Apnea Neurostimulator

May 8, 2025 | Emerging Technology

The study features a differentiated neurostimulation modality called proximal hypoglossal nerve stimulation.

The Race Toward Orexin Agonists Targeting Narcolepsy’s Root Cause

Apr 30, 2025 | Emerging Compounds

Drug candidates aim to address the root cause of narcolepsy type 1—orexin deficiency—with some also being explored for narcolepsy type 2 and idiopathic hypersomnia.

Incannex OSA Drug Candidate IHL-42X Sails Through Milestones

Feb 25, 2025 | Emerging Compounds

Incannex announced positive top-line results from the completed pharmacokinetics and safety study of IHL-42X, a novel, oral fixed-dose combination of acetazolamide and dronabinol for the treatment of OSA.

Peerbridge, Maker of Monitor for OSA and Heart Conditions, to Validate Diagnostic Capabilities of ECG Wearables

Jan 10, 2025 | Heart

The trial will validate the screening and diagnostic capabilities of Peerbridge Cor ambulatory ECG wearables.

Human Umbilical Cord Blood Infusion Improves Fatigue in Long-COVID

Dec 31, 2024 | Emerging Compounds

Clinical trial results show that HPC, cord blood effectively treats post-COVID fatigue, with 85% of patients experiencing relief.

NLS CEO Highlights Progress on Dual Orexin Agonist Platform and Upcoming Merger

Dec 11, 2024 | Emerging Compounds

NLS Pharmaceutics’ CEO provided updates on the company’s progress with its dual orexin receptor agonist platform for narcolepsy, financial restructuring, and its anticipated merger with Kadimastem Ltd.

Insomnia Drug Daridorexant Begins Phase 3 Study to Support South Korea Approval

Dec 9, 2024 | Insomnia

Daridorexant has already been approved in Japan (where it will be marketed as Quviviq) and other regions, including the US and Europe.

Laser-Based Pulse Oximeter Advances Toward FDA Submission

Dec 5, 2024 | Screeners

Zynex has completed its clinical verification trial for the NiCO laser-based pulse oximeter, a device designed to measure blood oxygen levels more accurately.

Preclinical Results Highlight Potential of Dual Orexin Platform for Narcolepsy

Dec 4, 2024 | Emerging Compounds

Preclinical findings from NLS Pharmaceutics demonstrate the therapeutic potential of dual orexin receptor agonists for narcolepsy and neurological disorders.

Investigational AXS-12 Reduces Cataplexy in Narcolepsy Patients

Nov 26, 2024 | Emerging Compounds

AXS-12, a norepinephrine reuptake inhibitor, significantly reduced cataplexy attacks in narcolepsy patients in the ENCORE phase 3 trial, demonstrating long-term efficacy, safety, and improvements in excessive daytime sleepiness and cognition.

Investigational Antiviral Therapy Reduces Long-COVID-Related Fatigue and Sleep Disturbance

Nov 18, 2024 | Emerging Compounds

A twice-daily, low-dose regimen demonstrated a clinically meaningful reduction in long-COVID-related fatigue and sleep disturbances compared to placebo.

Sublingual Bedtime Drug Candidate Improves Pain and Sleep in Fibromyalgia

Nov 18, 2024 | Emerging Compounds

Tonix Pharmaceuticals presented new data at the American College of Rheumatology’s 2024 meeting, demonstrating that its drug candidate TNX-102 SL significantly reduces pain and improves sleep quality in fibromyalgia patients.

Centessa Launches Phase 2 Trial of ORX750 for Narcolepsy and IH

Nov 14, 2024 | Emerging Compounds

Centessa Pharmaceuticals has initiated a phase 2 trial of ORX750, an oral orexin receptor 2 agonist designed to treat narcolepsy type 1, type 2, and idiopathic hypersomnia.